Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

doi:10.1038/s41591-023-02734-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.

Nature medicine - 1 Feb 2024

Heinrich Michael C, Jones Robin L, George Suzanne, Gelderblom Hans, Schöffski Patrick, von Mehren Margaret, Zalcberg John R, Kang Yoon-Koo, Razak Albiruni Abdul, Trent Jonathan, Attia Steven, Le Cesne Axel, Siontis Brittany L, Goldstein David, Boye Kjetil, Sanchez Cesar, Steeghs Neeltje, Rutkowski Piotr, Druta Mihaela, Serrano César, Somaiah Neeta, Chi Ping, Reichmann William, Sprott Kam, Achour Haroun, Sherman Matthew L, Ruiz-Soto Rodrigo, Blay Jean-Yves, Bauer Sebastian

Abstract excerpt

INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretinib 150 mg or sunitinib 50 mg. In the primary analysis, progression-free survival (PFS) with ripretinib was not superior to sunitinib. In clinical and nonclinical studies, ripretinib and sunitinib have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Neoplasms

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Naphthyridines

Share to Proto-Oncogene Proteins c-kit

Share to Sunitinib

Share to Urea

Source

Open in PubMed Open full text

Identifiers

PMID: 38182785
DOI: 10.1038/s41591-023-02734-5
PMCID: PMC10878977

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.PMID 38182785Read ↗

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.Semantic proximity Read ↗

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.Semantic proximity Read ↗

GIST: Molecular Profiling Suggests 2nd Therapy.Semantic proximity Read ↗

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Semantic proximity Read ↗

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.Semantic proximity Read ↗

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.Semantic proximity Read ↗

Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 PatientsSemantic proximity Read ↗

Precision medicine in gastrointestinal stromal tumors.Semantic proximity Read ↗

Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.